ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States and other countries.
Melodie Young, NP and Matthew Reynolds, PA-D discuss why ILUMYA is their preferred choice for lasting results and consistent efficacy.
VIDEO LIBRARY
Living with psoriasis, Art knows the ups and downs of managing the condition. But by his side, through it all, has been his wife, Kim. Art and Kim sit down to tell their story of how love, support, and a treatment plan with ILUMYA helped Art find the relief he’d been searching for.
Watch this video in 3D animation to see how ILUMYA precisely targets the IL-23 pathway of the inflammatory cycle of psoriasis.
†Secondary insurance is available through a beneficiary employee retiree program, spousal coverage, privately purchased Medigap policy, or TRICARE For Life wraparound benefits.
Links and Downloads
INDICATION
ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity
Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.
Infections
ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequatelly treated.
Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.
Pretreatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and
symptoms of active TB during and after treatment.
Immunizations
Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.
Adverse Reactions
The most common (>1 %) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.
Please see Full Prescribing Information in the Links and Downloads section above or at ILUMYApro.com.
About Sun Pharma
Sun Pharma is a global pharmaceutical company driven by a bold pursuit of science, fueled by an unwavering commitment to patients, and grounded by our values of integrity, quality, and innovation. Our core values define who we are, guiding our beliefs and behaviors as we strive to Reach People and Touch Lives.
We are advancing a pipeline of high-quality medicines across our Innovative Therapies, Generic Medicines, and Over-the-Counter Medicines. At Sun Pharma, we are relentless in our pursuit of Reaching People and Touching Lives.
For decades, Sun Pharma has established itself as a leading player in the U.S. market. Today, we are among the top pharmaceutical companies in the U.S., ranking #2 by prescriptions in the U.S. dermatology market. We continue to expand rapidly in the branded Innovative Therapies market, with dermatology, ophthalmology, and oncology as key focus areas.
|
|
 During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
 See full Prescribing Information, including BOXED WARNING
|
|
|
During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
See full Prescribing Information, including BOXED WARNING
|
|
|
||
|
During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
See full Prescribing Information, including BOXED WARNING
|
|
|
|
|
During and for a time after treatment, females should avoid pregnancy and males should use condoms.
See full Prescribing Information, including BOXED WARNING
|
|
|
See full Prescribing Information, including BOXED WARNING
|
During and for a time after ODOMZO treatment, females should avoid pregnancy and males should use condoms.
LEQSELVI should not be used in patients who are CYP2C9 poor metabolizers or taking moderate or strong CYP2C9 inhibitors.
It may cause serious side effects including serious infections, malignancies, thrombosis, gastrointestinal perforations, and certain laboratory abnormalities.
All trademarks are property of their respective owners.